Shots:
- Eli Lilly has reported P-III (LIBRETTO-432) trial data assessing Retevmo vs PBO in 151 pts with RET fusion-positive NSCLC following completion of definitive radiotherapy or surgery with curative intent, & other adjuvant therapy, if indicated
- Trial met its 1EP, showing improvement in investigator-assessed EFS in early-stage (II-IIIA) pts, plus OS data was immature but demonstrated a favorable trend; full data to be presented in future meeting, submitted to a journal & discussed with regulators globally
- Retevmo (LOXO-292) is a potent, highly selective RET kinase inhibitor designed to target RET-driven cancers, incl. those with CNS involvement
Ref: Eli Lilly | Image: Eli Lilly | Press Release
Related News: Eli Lilly Reports P-IIIb (TOGETHER-PsA) Trial on Taltz + Zepbound for Psoriatic Arthritis and Obesity or Overweight
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
